This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of other and unspecified parts of mouth입의 기타 및 상세불명 부분의 악성신생물 (구강암)

Contents and key points
ItemDetails
A. Classification codesICD-10: C06 (C06.0 cheek mucosa, C06.1 vestibule of mouth, C06.2 retromolar area, C06.8 overlapping sites, C06.9 unspecified) | Special Copayment Reduction: V193 (copayment 5% for care of the relevant condition for 5 years from the date of cancer patient registration)
B. SynonymsOral cancer, buccal mucosa cancer, cancer of the vestibule of the mouth, oral cancer, unspecified; Buccal mucosa carcinoma, Vestibule of mouth carcinoma, Oral cavity carcinoma NOS, Cheek mucosa cancer
C. Adult onsetLikelihood of first onset in adulthood very high — mostly diagnosed in the 40s–70s; buccal mucosa cancer occurs at younger ages in betel nut-chewing cultures
1. HistoryRecognition of the high incidence of buccal mucosa cancer in Southeast Asia, development of the clinical classification of vestibular cancer, establishment of combined surgery and radiation treatment in the 20th century
2. CausesBetel nut and chewing tobacco (main cause of buccal mucosa cancer), smoking, alcohol, poor oral hygiene, chronic mechanical irritation, HPV, immunosuppression
3. GeneticsTP53, CDKN2A, FAT1, NOTCH1, PIK3CA mutations, EGFR overexpression, betel nut-related specific mutational signature
4. General epidemiologyBuccal mucosa cancer: 2–10% of all oral cancers (Western countries), up to 40% in betel nut-chewing cultures such as India and Taiwan; male predominance, 40s–70s
5. PathophysiologyNonkeratinized mucosal premalignant lesions → multistep carcinogenesis; direct mucosal toxicity of betel nut components such as arecoline; EGFR, PI3K and Wnt pathways
6. SymptomsEarly: ulcer, leukoplakia or erythroplakia of the inner cheek; advanced: pain, trismus, odynophagia, neck mass; accompanied by oral submucous fibrosis
7. SignsUlcerative buccal mucosal mass, trismus due to pterygoid muscle invasion, skin invasion, cervical level I–II lymphadenopathy, oral submucous fibrosis
8. ScreeningVisual oral examination (retracting the cheek), regular dental checkups, intensive surveillance of high-risk groups (betel nut, smoking), follow-up of premalignant lesions
9. DiagnosisCT, MRI, PET-CT, biopsy, assessment of skin and pterygoid muscle invasion, AJCC 8th edition staging
10. TreatmentSurgery (wide excision + reconstruction), IMRT adjuvant radiotherapy, concurrent chemoradiotherapy, pembrolizumab and nivolumab, mouth-opening rehabilitation when oral submucous fibrosis is present
11. PrognosisBuccal mucosa cancer 5-year survival about 50–60% (early stage), 20–30% (advanced stage); skin invasion, lymph node metastasis and oral submucous fibrosis are poor prognostic factors
12. PreventionStopping betel nut and chewing tobacco (key), smoking cessation and moderate drinking, oral hygiene, HPV vaccine, regular checkups, early treatment of oral submucous fibrosis
13. ReferencesBray F et al. Global cancer statistics 2022. CA Cancer J Clin. 2024 ... and 9 other papers

1. History

ICD-10 code C06 covers malignant neoplasms of other and unspecified parts of the mouth, mainly including the buccal mucosa (cheek mucosa), the vestibule of mouth, the retromolar area (retromolar trigone), and overlapping tumors spanning two or more adjacent sites. Of these, buccal mucosa cancer is the most clinically important.

Historically high incidence of buccal mucosa cancer has been reported in regions where betel nut (areca) chewing is customary, such as Southeast Asia, South Asia and Taiwan. In these regions, buccal mucosa cancer is the most common oral cancer subtype, accounting for over 40% of all oral cancers. Buccal mucosal ulcers were frequently described in 19th-century case reports of oral cancer in India and Southeast Asia, and the carcinogenicity of betel nut was later demonstrated through epidemiological studies.

In Western countries, buccal mucosa cancer was a relatively rare cancer accounting for 2–10% of all oral cancers, but since the mid-20th century its incidence has risen in some regions with the growth of immigrant populations. Patterns of invasion according to the respective anatomical features of vestibular cancer and retromolar area cancer have also been described, and early invasion of the mandibular ramus and pterygoid muscles was found to be characteristic.

In the 20th century, surgical treatment of buccal mucosa cancer (wide excision, including resection of facial skin when the skin is invaded) was systematized, and the combination of radiotherapy and chemotherapy was standardized. Another important historical achievement was the recognition of oral submucous fibrosis as both a precursor condition of buccal mucosa cancer and a comorbidity that compounds the difficulty of treatment. In the 21st century, treatment options for recurrent and metastatic buccal mucosa cancer have expanded with the introduction of immunotherapy.


2. Causes

The risk factors for C06 oral cancer, particularly buccal mucosa cancer, differ in some respects from those of other oral cancer subtypes.

Betel nut and chewing tobacco

Betel nut (areca nut) is the strongest single risk factor for buccal mucosa cancer. Arecoline, the active component of betel nut, causes direct DNA damage, oxidative stress and mucosal inflammation. Betel quid, a mixture of betel leaf, lime and tobacco, has an even stronger carcinogenic effect. Smokeless tobacco also delivers carcinogens through direct contact with the buccal mucosa.

Smoking and alcohol consumption

Carcinogens in tobacco smoke act directly on the buccal mucosa, and alcohol increases mucosal permeability, creating a carcinogenic environment. Combined exposure to smoking and alcohol has a synergistic carcinogenic effect.

Oral submucous fibrosis and chronic irritation

Oral submucous fibrosis (OSF) is a premalignant condition strongly associated with betel nut chewing, in which the risk of malignant transformation increases greatly along with progressive fibrosis of the buccal mucosa. Chronic irritation of the buccal mucosa by ill-fitting prostheses and sharp teeth is also a risk factor. HPV and immunosuppression also act as supplementary risk factors.


3. Genetics

The molecular genetics of C06 oral cancer, including buccal mucosa cancer, follows the general pattern of oral squamous cell carcinoma, but a specific mutational signature due to betel nut exposure is observed.

Major somatic mutations

TP53 mutations (about 50–70%) are the most common. CDKN2A deletion/methylation and activating mutations of FAT1, NOTCH1 and PIK3CA are observed at frequencies of 10% or more. CASP8 mutations confer resistance to apoptosis. The mutational signature associated with betel nut exposure is characterized by APOBEC enzyme-related C→T and C→G transitions. EGFR overexpression is found in 80–90% of buccal mucosa cancers and provides the theoretical basis for targeted therapy.

Molecular changes related to oral submucous fibrosis

In OSF, hyperactivation of the TGF-β pathway, COX-2 overexpression and increased VEGF are observed, promoting mucosal fibrosis and angiogenesis. TP53 mutations and CDKN2A inactivation accumulate during malignant transformation of OSF. PD-L1 CPS and TMB are used to determine the indication for immunotherapy in recurrent or metastatic buccal mucosa cancer.

Hereditary syndromes

Fanconi anemia and Li-Fraumeni syndrome increase the risk of oral cancer, including buccal mucosa cancer.


4. General epidemiology

The epidemiology of C06 oral cancer, particularly buccal mucosa cancer, has a distinct geographic distribution.

Global epidemiology

In Western countries (North America, Northern Europe), buccal mucosa cancer accounts for about 2–10% of all oral cancers. However, in betel nut-chewing cultures such as India, Pakistan, Bangladesh, Taiwan and the Philippines, buccal mucosa cancer is the most common oral cancer subtype, accounting for 30–40% of all oral cancers. In some regions of India, buccal mucosa cancer is reported as the most common oral cancer.

Epidemiology in Korea

In Korea, betel nut chewing is rare, so the incidence of buccal mucosa cancer is lower than in Western countries, but smoking- and alcohol-related buccal mucosa cancer does occur. Overall incidence statistics for C06 in Korea are often not compiled separately, but it forms part of head and neck squamous cell carcinoma overall. Attention to betel nut-related buccal mucosa cancer is needed in Southeast Asian immigrant groups.

Sex and age

Men have a higher incidence than women, and the main age of onset is the 40s–70s. In betel nut-chewing cultures, many cases also occur at younger ages (30s–50s).


5. Pathophysiology

Buccal mucosa cancer arises from nonkeratinized squamous epithelium and progresses to invasive cancer via premalignant lesions (particularly oral submucous fibrosis, leukoplakia and erythroplakia).

Betel nut-mediated carcinogenic mechanisms

Arecoline directly induces DNA double-strand breaks and generates reactive oxygen species (ROS), causing oxidative DNA damage. It hyperactivates the TGF-β pathway, promoting fibroblast proliferation and collagen deposition in the buccal mucosa and thereby causing OSF. p53 mutations and CDKN2A inactivation accumulate in OSF mucosa, increasing the risk of carcinogenesis.

Major signaling pathways

Hyperactivation of the EGFR/RAS/MAPK pathway and the PI3K/AKT/mTOR pathway promotes cell proliferation and invasion. The Wnt/β-catenin pathway also contributes to invasive growth. In the tumor microenvironment, immunosuppressive cytokines (TGF-β, IL-10) weaken antitumor immunity. Chronic inflammation in OSF maintains a tumor-promoting environment through COX-2 overexpression.


6. Symptoms

Early symptoms

The early symptoms of buccal mucosa cancer are a painless ulcer, leukoplakia (white patch), erythroplakia (red patch) or swelling on the inner cheek. When oral submucous fibrosis precedes it, stiffness of the buccal mucosa and restricted mouth opening may be present from the start. Early on, it is often confused with simple stomatitis or a traumatic ulcer, delaying diagnosis.

Advanced symptoms

As the tumor grows, cheek pain, discomfort on chewing and intraoral bleeding appear. With invasion of the pterygoid muscles, trismus develops, and when OSF is present, trismus appears earlier and more severely. With skin invasion, induration of the cheek skin and an orocutaneous fistula may form. A neck mass due to cervical lymph node metastasis appears.

Symptoms related to oral submucous fibrosis

When OSF is present, difficulty opening the mouth, an intraoral burning sensation, a foreign body sensation on swallowing, and a pale, indurated appearance of the oral mucosa are characteristic.


7. Signs

Findings on oral inspection

An ulcerative mass with irregular margins or an exophytic mass is seen on the buccal mucosa. When OSF is present, the tumor arises on a background of pale, firmly fibrosed buccal mucosa. Vestibular cancer lies in the groove between the gums and cheek (oral vestibule), requiring direct inspection. Retromolar area (retromolar trigone) cancer lies behind the last mandibular molar.

Neck and systemic findings

Ipsilateral cervical level I–II lymphadenopathy is observed. When the outer skin of the cheek is invaded, induration, retraction and fistula of the skin are observed. Pterygoid muscle invasion and mandibular ramus invasion are confirmed on CT. PET-CT is used to evaluate distant metastasis.


8. Screening

Because buccal mucosa cancer arises at a site that can be directly inspected within the mouth, a properly performed visual oral examination is the most effective screening tool.

Technique of oral visual examination

While gently retracting the cheek with a finger, the entire buccal mucosa, the oral vestibule and the retromolar area are inspected systematically. VELscope (an autofluorescence device) and toluidine blue staining are used as adjuncts. In patients with trismus, endoscopy-assisted inspection is needed.

Surveillance of high-risk groups

Betel nut and chewing tobacco users, smokers and drinkers, and OSF patients need intensive surveillance at 3–6-month intervals. When a new ulcer or indurated mass develops in an OSF patient, immediate biopsy is recommended.


9. Diagnosis

Imaging

CT: evaluates tumor size, skin invasion, the extent of pterygoid muscle and mandibular ramus invasion, and cervical lymph node metastasis. MRI: superior for evaluating the extent of soft tissue invasion, perineural invasion (inferior alveolar nerve, buccal nerve) and the extent of OSF. PET-CT: used to evaluate distant metastasis and cervical lymph node metastasis.

Tissue biopsy and pathology

More than about 90% of buccal mucosa cancers are squamous cell carcinoma. Biopsy in the presence of OSF can be technically difficult because of the fibrotic tissue. The pathology report must include depth of invasion, perineural invasion, lymphovascular invasion, surgical margins and skin invasion. T4a classification is invasion of cortical bone, nasal cavity, maxillary sinus or facial skin; T4b is invasion of the pterygoid space, skull base or internal carotid artery.


10. Treatment

Surgery

Wide excision of the buccal mucosa is the first-line treatment. When the skin is invaded, resection of facial skin is included, and the defect is reconstructed with a radial forearm free flap (RFFF) or anterolateral thigh free flap (ALT flap). When there is a skin defect, external facial reconstruction with an adjacent skin flap or free flap is also performed. Ipsilateral selective neck dissection is performed concurrently. In patients with OSF, physical therapy and mouth-opening rehabilitation after surgery are essential.

Adjuvant radiation and chemoradiotherapy

When there are high-risk pathological findings (positive margins, ENE, perineural invasion, pN2 or higher), adjuvant IMRT (60–66 Gy) or concurrent chemoradiotherapy with cisplatin is given.

Recurrent and metastatic oral cancer

Based on KEYNOTE-048, pembrolizumab monotherapy (CPS≥1) or pembrolizumab combination is used as first-line treatment. Nivolumab, based on CheckMate 141, is second-line treatment. Cetuximab+EXTREME combination is also an option.


11. Prognosis

Buccal mucosa cancer has a relatively poorer prognosis than other oral cancer subtypes, and skin invasion, coexisting OSF and trismus are associated with a poor prognosis.

Survival by stage

Stage5-year overall survival rate
Stage I-IIAbout 50–65%
Stage IIIAbout 30–45%
Stage IV (including skin invasion)About 15–30%

When buccal mucosa cancer invades the skin, it is classified as T4 or higher and the prognosis worsens sharply. Cervical lymph node metastasis, perineural invasion and positive surgical margins are also independent poor prognostic factors. In patients with OSF, malnutrition due to trismus and recovery of function after treatment are more difficult.


12. Prevention

Primary prevention

Stopping betel nut and chewing tobacco is the key to preventing buccal mucosa cancer. Health education and programs supporting cessation of smoking and betel nut use are effective. Smoking cessation and moderate drinking suppress the occurrence of smoking- and alcohol-related buccal mucosa cancer. The HPV vaccine contributes to preventing HPV-related oral cancer.

Secondary prevention

During regular oral examinations, the entire buccal mucosa is inspected systematically. Patients with premalignant lesions such as OSF, oral leukoplakia and erythroplakia are intensively followed up at 3–6-month intervals, and dysplastic lesions are treated immediately when found.


13. References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834

  2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org

  3. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy (KEYNOTE-048). The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7

  4. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141). New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252

  5. Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.

  6. Kim M, Kim JH, Kim JY, et al. An epidemiological trend analysis of oral cancer in Korea from 2001 to 2021. BMC Oral Health. 2025;25:567. DOI: 10.1186/s12903-025-06351-1

  7. D'Cruz AK, Vaish R, Kapre N, et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. New England Journal of Medicine. 2015;373(6):521-529. DOI: 10.1056/NEJMoa1506007

  8. Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence. Oncotarget. 2016;7(5):5771-5784. DOI: 10.18632/oncotarget.6532

  9. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology. 2010;11(8):781-789. DOI: 10.1016/S1470-2045(10)70017-6

  10. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. DOI: 10.3322/caac.21763